BridgeBio reports Q4 net product revenue $146M; three positive Phase 3 trials

BridgeBio Pharma, Inc.

2025-FY EPS reported -$3.78 vs consensus -$0.76 ▼ miss (-399.3%)

Q4 net loss $192.9M ($1.00/share); FY net loss $724.9M ($3.78/share).
Attruby (ATTR-CM) net product revenue $146.0M in Q4; 7,804 patient prescriptions as of Feb 20.
Phase 3 FORTIFY (LGMD2I/R9) met endpoints; 2.6-point NSAD improvement vs placebo at 12 months.
Phase 3 PROPEL 3 (infigratinib, achondroplasia) met primary endpoint; mean AHV +2.10 cm/year vs placebo.
Cash $587.5M at Dec 31; completed $632.5M convertible notes Jan 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.